Assessment of Multivalent Vaccine Strategies for Combatting Shigella and Salmonella Infections in Preclinical Studies - Takeaways - MDSpire

Assessment of Multivalent Vaccine Strategies for Combatting Shigella and Salmonella Infections in Preclinical Studies

  • By

  • Roberta Di Benedetto

  • Rebecca Nappini

  • Salvatore Gemmellaro

  • Federica Boretto

  • Valentina Caradonna

  • Martina Carducci

  • Paola Cescutti

  • Omar Rossi

  • Francesca Mancini

  • Francesco Berlanda Scorza

  • Simona Rondini

  • Carlo Giannelli

  • Renzo Alfini

  • Francesca Micoli

  • April 22, 2026

  • 0 min

Share

  • 1

    Shigellosis is a severe intestinal infection with high prevalence in children under five in low- and middle-income countries.

  • 2

    The World Health Organization prioritizes the development of new interventions for Shigella due to rising antimicrobial resistance.

  • 3

    A novel hexavalent vaccine combines a tetravalent Shigella vaccine with a bivalent Salmonella vaccine targeting typhoid and paratyphoid fever.

  • 4

    The combined vaccine strategy aims to enhance immunogenicity, reduce delivery costs, and improve vaccination coverage in endemic regions.

  • 5

    This multivalent vaccine approach could significantly contribute to reducing disease burden and addressing antimicrobial resistance.

Original Source(s)

Related Content